MedPath

Multi-center Assessment of Grafts in Coronaries: Long-term Evaluation of the C-Port Device

Phase 4
Completed
Conditions
Heart Disease
Interventions
Device: Anastomosis (C-Port® )
Registration Number
NCT01478061
Lead Sponsor
Cardica, Inc
Brief Summary

The Study plan is a post-market prospective, multi-center, open-label registry. The vein graft failure rates for the currently commercialized C-Port devices will be compared to an a priori rate taken from the peer-reviewed literature.

Detailed Description

To satisfy the requirements set forth in post-market surveillance orders issued by the US FDA to Cardica, Inc., the following outcomes will be evaluated:

1. Acute, midterm, and one-year graft failure rates for coronary revascularization using the C-Port® xA™ Distal Anastomosis System, C-Port® FlexA™ Distal Anastomosis System, and C-Port® XCHANGE™ Distal Anastomosis System when in general use in the United States compared to hand-sewn anastomoses.

2. Technical failure rates when attempting to complete an anastomosis using the C-Port xA, FlexA, and XCHANGE Distal Anastomosis Systems.

3. The technical success rate of hand-sewn anastomoses following technical failures of the C-Port devices and the hand-sewn graft patency rates and clinical sequelae at one year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
115
Inclusion Criteria
  • Able to give informed consent.
  • Willing and able to have follow-up visits and examinations.
  • Less than 80 years old.
  • Have an ejection fraction of >30 %.
  • Have a life expectancy of >1 year.

Pre-Operative

Exclusion Criteria
  • Currently participating in other clinical trials that would conflict with this protocol.
  • Unable to meet study requirements.
  • Currently pregnant.
  • Require preoperative use of an intraaortic balloon pump.
  • Have a history of a bleeding disorder or history of a thromboembolic disease requiring anticoagulation therapy.
  • Have congestive heart failure or been classified as NYHA Class IV.
  • Have an aspirin allergy or other contraindications to aspirin use.
  • Previous coronary artery bypass surgery.
  • Vasculitis or other nonatherosclerotic cause for coronary artery disease.

Intra-Operative Exclusion Criteria:

  • At least one target vessel site where the C-Port anastomosis will be placed that is free from severe calcification or severe atheromas
  • Target vessel wall properties where the C-Port anastomosis will be placed are suitable for hand-sewn anastomosis
  • Target vessel diameter is ≥ 1.3 mm
  • Target vessel has a single wall thickness ≤ 0.75mm
  • Hemodynamically stable

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
anastomoses in blood vessels and graftsAnastomosis (C-Port® )-
Primary Outcome Measures
NameTimeMethod
Graft patency rates for coronary revascularization when in general use in the United States compared to hand-sewn anastomoses.12 months

a. Acute, midterm, and one-year graft patency rates for coronary revascularization when in general use in the United States compared to hand-sewn anastomoses.

Secondary Outcome Measures
NameTimeMethod
Technical Failure RatesDay 1

Technical failure rates when completing an anastomosis using the C-Port products.

Technical success rate of hand-sewnDay 1 and 12 months

The technical success rate of hand-sewn anastomoses following technical failures of the C-Port products and the hand-sewn graft patency rates and clinical sequelae at one year.

Trial Locations

Locations (7)

Akron General Medical Center

🇺🇸

Akron, Ohio, United States

Cardiopulmonary Research Science & Technology Institute

🇺🇸

Dallas, Texas, United States

Wisconsin Heart

🇺🇸

Wauwatosa, Wisconsin, United States

University of Arkansas

🇺🇸

Little Rock, Arkansas, United States

Genesis Medical Center

🇺🇸

Davenport, Iowa, United States

Methodist Hospital - Houston

🇺🇸

Houston, Texas, United States

Lenox Hill Hospital

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath